

Is there evidence to link acid reflux with chronic sinusitis or any nasal symptoms? A review of the evidence*

E.P. Flook¹ and B.N. Kumar²

¹ ENT Registrar North Western Deanery, Hope Hospital, Salford Royal Foundation NHS Trust, United Kingdom

² ENT Consultant, Royal Albert Edward Infirmary, Wrightington, Wigan and Leigh NHS Trust, Wigan, United Kingdom

SUMMARY

Background: Acid reflux into the oesophagus, larynx, pharynx or nasopharynx has been suggested as a causal factor in chronic rhino-sinusitis (CRS), which can then be refractory to nasal treatments. The aim of this review was to conclude on the strength of the link between GORD, LPR, nasopharyngeal reflux, nasal symptoms and CRS.

Method: Medline and Embase search.

Results: Nineteen papers describing varying studies on CRS, GORD, LPR and PPI therapy were found. Four adult case-controlled studies showed more acid reflux events/symptoms in refractory CRS patients. Paediatric cohort studies showed more reflux events in rhinosinusitis patients than the general paediatric population, but they are not conclusive. Many papers do not use robust CRS diagnostic criteria for inclusion into studies and take no confounding factors into consideration.

Conclusion: The evidence of a link is poor with no good randomised controlled trials available. The few adult studies that show any link between acid reflux and nasal symptoms are small case-controlled studies with moderate levels of potential bias. There is not enough evidence to consider anti-reflux therapy for adult refractory CRS and there is no evidence that acid reflux is a significant causal factor in CRS.

Key words: reflux, rhinosinusitis, nasal symptoms, pH monitoring, LPR, GORD

INTRODUCTION

It has been questioned whether acid reflux (gastroesophageal reflux (GORD) and laryngopharyngeal reflux (LPR)) can lead to many different nasopharyngeal symptoms, which in combination can mimic chronic rhinosinusitis (CRS). There is debate as to whether acid reflux is a causal factor in CRS and also whether anti-reflux therapy can improve symptoms of refractory CRS. Similar symptoms can be described in GORD, LPR, and CRS conditions and clinical confusion with regard to the correct diagnosis can lead to inadequate or sometimes inappropriate management.

Acid reflux and nasal symptoms have been the focus of a wide variety of papers in the past that are not suitable for a meta-analysis review due to the different variables measured and techniques used. The aim of this review was to gather all the published evidence around this subject, evaluate the quality and relevance, and conclude on the strength of the link

between GORD, LPR, nasopharyngeal reflux and nasal symptoms and CRS and discuss how the clinician would best use this evidence in their own practice.

In a paediatric population, gastroesophageal reflux disease (GORD) is associated with an increase in the risk of sinusitis, laryngitis, asthma, pneumonia, and bronchiectasis⁽¹⁾. There is no large unbiased randomised controlled trial from which we can take reliable evidence to demonstrate this link. Small studies make suggestions only, which makes it difficult for the clinician to apply the results to their own patients. Up to 10% of infants can have GORD⁽²⁾ while children older than 12 months should have a similar rate of GORD as adults^(2,3). Smaller studies not accounting for age and confounding factors (weight, food before sleeping, sleeping position, asthma) have shown much higher rates of reflux with 25% of asymptomatic children having GORD and 8% having nasopharyngeal reflux⁽⁴⁾.

*Received for publication: February 22, 2010; accepted: June 8, 2010

DOI:10.4193/Rhino10.054

SEARCH METHOD

Published studies were identified using Medline (1950 – July 2009) and EMBASE (1980 – July 2009). Search terms used included: ‘gastroesophageal reflux’, ‘GERD’, ‘GORD’, ‘laryngopharyngeal reflux’, ‘nasopharyngeal reflux’, ‘acid laryngitis’, ‘chronic rhinosinusitis’, ‘chronic sinusitis’, ‘CRS’, ‘post nasal drip’, and ‘nasal symptoms’. Searches were not restricted by language. Reference lists from identified articles were searched and cross-referenced to obtain further relevant articles.

This and other such literature reviews are of course at risk of publication bias through non-inclusion of unpublished studies with non-significant or less impressive results.

The identified studies were assessed for eligibility and included only if they explored an association between nasal symptoms and acid reflux.

The identified studies were individually assessed using the Critical Appraisal Skills Programme (Oxford, UK) tools⁽⁵⁾. The papers were then stratified into low, moderate and high risk of bias and quality of study.

CRS has many symptoms associated with it. Some symptoms are more indicative of sinus pathology (green rhinorrhoea with nasal congestion) whereas others are much less specific to their aetiology (post-nasal drip, facial pain, nasal obstruction). The EPOS paper defines rhinosinusitis as inflammation of the nose and the paranasal sinuses characterised by a combination of symptoms and signs⁽⁶⁾ (Table 1). Although we should all strictly adhere to these criteria when diagnosing CRS, it is easy to label a patient with CRS when they have a vague symptom profile or with an emphasis on the less specific symptoms. Validated symptom scores exist and can be used to demonstrate symptom severity and change after treatment.

Gastric enzymes and acid inflame the larynx and pharynx causing LPR. Symptoms can include hoarseness, chronic cough and throat clearing but also more subjective symptoms like globus sensation or sensation of excessive or thick mucus and post-nasal drip. Symptoms can be scored on the Reflux Symptom Index⁽⁷⁾ (Table 2) which can be used to aid diagnosis and again can be used to assess treatment outcomes but should not be relied on, as the scores are a summation of subjective responses. Signs within the larynx include posterior commissure oedema and arytenoid swelling. Acid reflux into the hypopharynx can easily reflux into the nasopharynx especially

Table 1. EPOS clinical definition of rhinosinusitis⁽⁶⁾.

Symptoms	either nasal blockage / obstruction / congestion or nasal discharge (anterior / posterior nasal drip) ± facial pain/pressure ± reduction or loss of smell
Endoscopic signs	polyps and / or mucopurulent discharge primarily from middle meatus and / or oedema / mucosal obstruction primarily in middle meatus
and / or CT changes	mucosal changes within the ostiomeatal complex sinuses.

Table 2. Reflux Symptom Index (RSI)⁽⁷⁾. A RSI > 10 could indicate significant laryngopharyngeal reflux.

Within the last MONTH, how did the following problems affect you?	0 = No Problem 5 = severe problem					
1. Hoarseness or a problem with your voice	0	1	2	3	4	5
2. Clearing your throat	0	1	2	3	4	5
3. Excess throat mucous or postnasal drip	0	1	2	3	4	5
4. Difficulty swallowing food, liquids, or pills	0	1	2	3	4	5
5. Coughing after you ate or after lying down	0	1	2	3	4	5
6. Breathing difficulties or choking episodes	0	1	2	3	4	5
7. Troublesome or annoying cough	0	1	2	3	4	5
8. Sensations of something sticking in your throat or a lump in your throat	0	1	2	3	4	5
9. Heartburn, chest pain, indigestion, or stomach acid coming up	0	1	2	3	4	5
Total						

when lying flat, but the effect of this is unknown. GORD has different symptoms and treatment regimes and should be considered as a separate entity from LPR, where possible.

pH probe testing can be performed to objectively measure acid reflux into oesophagus or using dual monitoring probes can measure reflux into the hypopharynx or nasopharynx for comparison and assessment of the level of reflux.

SEARCH RESULTS

Identified studies

Nineteen studies were identified that were suitable. Seven specifically looked at paediatric cases and 12 used pH oesophageal probes to objectively detect gastroesophageal, laryngopharyngeal or nasopharyngeal reflux.

The literature search identified only 1 randomised controlled trial and all other papers were prospective cohort trials with or without controls (evidence grade II a and II b) or retrospective case analyses (evidence grade III).

Quality of the papers and level of potential bias in their results showed that all papers have moderate or high risk of bias (Table 3 and 4).

The variety of papers using different techniques, criteria and investigating different angles of this problem means that most of the papers cannot be directly compared to each other.

Paediatric studies

The paediatric studies (Table 3) consisted of 4 studies using pH studies and 4 studies trialling anti-reflux therapy.

pH studies

Phipps found 19 of 30 (63%) children to have GORD from a population of children with medically refractory CRS with evidence of sinus disease on CT scanning, being on intranasal steroids throughout (8). Monteiro showed that 10% of children with a diagnosis of CRS (made clinically with additional plain x-ray or CT scans) also have gastroesophageal reflux. However, this was a small group of 10 and so only 1 child showed a correlation between CRS and GORD that is not

Table 3. Paediatric studies.

Study	Type	Study size	Selection criteria	Measurement	Bias risk	Result
Phipps et al. 2000 ⁽⁸⁾	Cohort	30	Consecutive CRS clinically + evidence on CT	Oesophageal + nasopharyngeal pH monitoring	mod	19 had GORD, 6 also had nasopharyngeal reflux
Monteiro et al. 2005 ⁽⁹⁾	Cohort	10	selected clinically / radiologically CRS	Oesophageal pH monitoring	high	1 of 10 had significant GORD
Barbero 1996 ⁽¹⁰⁾	Cohort	22	Selected clinically indicated to undergo sinus surgery for CRS	Oesophageal pH monitoring + improvement after anti-reflux therapy treatment	mod	16 had GORD. 10 improved with anti-reflux therapy
Keles et al. 2005 ⁽⁶⁾	Prospective case – control	30 vs 12	Adenoid hyperplasia vs normal	Upper and lower oesophageal pH monitoring	mod	LPR 47 vs 8% GORD 65 vs 25%
Bothwell et al. 1999 ⁽¹²⁾	Retrospective case series	28	Selected clinically indicated to undergo sinus surgery for CRS	subjective symptoms and surgery avoidance after anti-reflux therapy	high	25 of 28 improved enough to avoid sinus surgery
Halstead ⁽¹³⁾	Case series	11	Rhinitis, sinusitis and otitis patients having pH testing	pH testing and symptoms after antireflux medication	high	6 of 11 improved with treatment
Mengale et al. 2006 ⁽¹⁴⁾	Retrospective Case series	45	GORD + nasal symptoms	Nasal symptom improvement after anti-reflux and other treatments	high	80 - 85% nasal symptoms improved

significantly different from normal population (9). Barbero tested 22 children already on the waiting list for sinus surgery showing 16 (73%) had significant GORD, with 9 (41%) having no specific GORD symptoms i.e. silent reflux⁽¹⁰⁾.

Phipps also found 20% of the CRS children to have nasopharyngeal reflux⁽⁸⁾.

Children with adenoid hyperplasia had more reflux than “normal” children with dual probe pH monitoring at distal and proximal oesophagus, the authors assuming pharyngeal reflux if upper oesophagus is involved (LPR 46% vs 8% and GORD 63% vs 25%)⁽⁶⁾. Although a histological analysis of adenoidal tissue showed no pepsin within hyperplastic adenoids thereby claiming there is little evidence that reflux is a major cause of adenoidal hyperplasia⁽¹¹⁾.

Anti-reflux therapy studies

When treatment with anti-reflux therapy was trialled in CRS children, 45%⁽¹⁰⁾ and 89%⁽¹²⁾ improved. Bothwell's retrospective study commented that 89% of patients awaiting sinus surgery for CRS no longer required surgery following anti-reflux therapy. This does not take into account any other factor of why the surgery was avoided, (i.e. natural resolution, seasonal variation or other nasal therapies) nor how long the anti-reflux therapy was taken or their compliance⁽¹²⁾. Barbero found that of 22 children with medically refractory CRS suitable for sinus surgery, 13 improved (10 completely) with anti reflux therapy⁽¹⁰⁾.

Treatment of nasal symptoms with anti-reflux therapy has shown some success but diagnostic criteria or good trial meth-

odology was lacking. In Halstead's study, 55% of patients had improved symptoms with anti-reflux therapy but this study of 11 children included rhinitis, sinusitis or otitis patients with no clear diagnostic criteria or any comment on the degree of improvement⁽¹³⁾. Mengale saw retrospectively that GORD patients aged 3 months to 12 years (pH probe proven) treated with antireflux drugs, antiallergic drugs, and surgical procedures therapy saw their nasal obstruction improve in 85% of cases and nasal secretions improve in 80% and nasal itching in 80%⁽¹⁴⁾. These children were not diagnosed with CRS and may well have had rhinitis which would have responded to these treatments regardless of any GORD.

Adult studies

In the adult studies, there was only 1 randomised controlled study (evidence level I). In 5 case controlled studies (level II a), different factors were examined using pH probes (nasopharyngeal, hypopharynx as well as oesophageal placement), pepsin level analysis and quality of life questionnaires. Other adult studies were 6 non-controlled cohort studies (level II b) (Table 4).

pH studies

LPR events were more frequent in the CRS group when compared to a non-CRS group (88% vs 55%⁽¹⁵⁾, 76% vs 24%⁽¹⁶⁾ and 64% vs 18%⁽¹⁷⁾). When a pH probe was used in the nasopharynx, it showed acid (pH < 5) reflux events to be higher in refractory CRS patients (74% vs. 38%)⁽¹⁶⁾. Although these studies were controlled, there was no comment on matching

Table 4. Adult studies

Study	Type	Study size	Selection criteria	Measurement	Bias risk	Result
Ozman et al. 2005 ⁽¹⁵⁾	Case-controlled	33 vs 20	Awaiting sinus surgery for CRS vs no CRS	Pharyngeal pH g monitorin and pepsin nasal lavage	mod	More reflux in CRS group + more nasal pepsin
DelGaudio et al. 2005 ⁽¹⁶⁾	Case-controlled	38 vs 10 vs 20	Surgically refractory CRS vs resolved CRS vs no CRS	Nasal, pharyngeal and oesophageal pH monitoring	mod	More reflux in refractory CRS group
Ulualp SO et al. 1999 ⁽¹⁷⁾	Case-controlled	11 vs 11	Refractory CRS vs no CRS	Pharyngeal and oesophageal pH monitoring	mod	CRS: 7 of 11 had pharyngeal reflux events No CRS: 2 of 11
Wong et al. 2004 ⁽¹⁸⁾	Cohort	37	CRS	4 channel pH probe	mod	32% had GORD. LPR and nasopharyngeal reflux rare
Jecker et al. 2005 ⁽¹⁹⁾	Case-controlled	20 vs 20	Recurrent CRS vs no CRS	pH monitoring	mod	More GORD in CRS group but not more LPR.
Kibblewhite et al. 1990 ⁽²⁰⁾	RCT	20	Post-nasal drip or globus	Symptom improvement with PPI or placebo	high	No difference
Kleemann et al. 2005 ⁽²¹⁾	Cohort	79	3/52 Post FESS nasal symptoms	Symptoms after 2/52 PPI	high	60 of 79 improved nasal symptoms
DiBiase et al. 2002 ⁽²²⁾	Cohort	11	Consecutive clinical CRS	Symptoms scoring. nasolayngoscopy after PPI therapy	mod	Some symptom improvement, not correlated with appearances
Pincus RL et al. 2006 ⁽²³⁾	Cohort	30	Medically and surgically refractory CRS	pH monitoring and symptom improvement using PPI	high	25 of 30 had LPR or Nasal reflux events. 14 of 15 improved with PPI
Dinis et al. 2006 ⁽²⁴⁾	Case-controlled	15 vs 5	Medically refractory CRS vs no CRS	Biopsy analysis for pepsin + H. pylori	high	No intranasal pepsin identified. No difference in H.pyori between groups
Delehayé et al. 2009 ⁽²⁵⁾	Cohort	50	GORD	Saccharin test time + nasal symptom scoring	mod	37 of 50 had prolonged nasal mucociliary clearance time. All normal SNOT20 scores.
Wise et al. 2006 ⁽²⁶⁾	Mixed cohort	68	Refractory CRS & resolved CRS & no CRS	Nasal, pharyngeal and oesophageal pH monitoring. Post nasal drip symptom scoring	mod	More reflux seen in patients complaining of post nasal drip.

the controls to eliminate significant confounding effects such as age, weight, medications, co-morbidities or hiatus hernia. In a different study of CRS patients, a 4-channel pH probe showed 32% patients had GORD but LPR was rare and nasopharyngeal reflux was very rare⁽¹⁸⁾.

The relationship of CRS with gastroesophageal reflux has also been studied. A cohort of recurrent CRS patients had 10 times as many gastroesophageal reflux events compared with non-CRS patients but these differences were not seen in the acid reflux measured in their hypopharynx. However, this study

chose to look at patients with CRS with polyps, which is a significantly different cohort to refractory CRS without polyps⁽¹⁹⁾.

Anti-reflux therapy studies

When treatment with a proton pump inhibitor (PPI) was trialled, cimetidine had no benefit over a placebo to globus or postnasal drip symptoms⁽²⁰⁾. This trial had only 20 patients (9 and 11 in each arm with poor group matching for post nasal drip symptoms). The patients did not have CRS or pH testing to prove the reflux; they monitored globus, postnasal drip,

chronic throat clearing and heartburn using a non-validated symptom scoring system. Treatment was with cimetidine 300 mg qds po, which is rarely used in current practice. This trial has many failings with significant bias and should not be used in a discussion on this topic.

Kleeman's study started PPI treatment if patients still had CRS symptoms 3 weeks after FESS and found that PPIs helped nasal symptoms in 76% of patients⁽²¹⁾. This study did not account for continued symptom improvement that can occur naturally beyond 3 weeks after FESS nor was there any comment on whether any other medical nasal treatment was used. A small study with regular heartburn, but not CRS, showed that 25-84% of patients had nasal symptom improvement⁽²²⁾. Fourteen out of 15 (93%) patients with refractory nasal congestion, discharge or facial pain/headaches had improvement of these symptoms with PPI treatment for 1 month⁽²³⁾. In 7 of these patients their symptoms resolved completely although subjective symptom scoring and recall bias may be factors.

Nasal testing

When pepsin levels were taken by nasal lavage using fluorometric assay, they correlated well with reflux events⁽¹⁵⁾. Pepsin levels were not raised in medically refractory CRS patients from another study that biopsied inflamed sino-nasal tissue⁽²⁴⁾.

Thirty seven out of 50 patients with GORD without CRS had prolonged nasal saccharin test compared to normal values⁽²⁵⁾. This demonstrates an objective link. Those with gastroesophageal symptoms had higher SNOT-20 scores compared to those without symptoms, but not high enough to be truly abnormal.

Symptom questionnaires

Patients (CRS and Non-CRS) with LPR and nasopharyngeal reflux as shown by pH probe testing had statistically significantly more postnasal drip symptoms when measured by the SNOT20 and MRSI questionnaires (Sinonasal Outcome Test-20 and Modified Reflux Symptom Index)⁽²²⁾. This study used a mixed cohort of refractory CRS, resolved CRS and non-CRS patients and studied them all together. It established no difference between the patient groups and had some strange subgroup results that reflux of pH < 4 did not cause symptoms but a milder pH < 5 was significant.

DISCUSSION

The different studies, inclusion criteria, testing techniques and varied treatment regimes make comparison, analysis and conclusions difficult. There are no scientifically high quality papers on this subject. This alone demonstrates that the evidence of a link is weak. There are a few case-controlled papers that are mostly well constructed but confounding factors are not eliminated. Table 4 shows that on analysis all the papers had moderate or high risk of bias. It is uncertain that all patients within these studies fulfilled the EPOS definition of CRS (most were published before EPOS) and may have had less stringent criteria.

However, several studies have similar findings. Four studies of patients with CRS showed positive pH tests confirming

GORD, LPR or nasopharyngeal events in a higher percentage than the incidence in non-CRS patients. Also 3 papers showed that some nasal symptoms improve with anti-reflux therapy but treatment regimes, symptom groups and level of improvements were vague and variable. There is no evidence that true refractory CRS is resolved by anti-reflux therapy to any significant extent.

Treatment of LPR is not standardised with proton pump inhibitors (PPIs) being used regularly with little evidence and there are opinions that the use of alginates, barrier protection and anti-inflammatories are more effective. This makes trials just using PPIs as treatment questionable and potentially redundant. There were no studies of nasal symptoms using other anti reflux therapy other than PPIs or H2 antagonists.

The proven presence of peptic enzymes on nasal mucosa and the presence of stomach acid causing nasal mucociliary hypofunction may cause some symptoms but there is no evidence of reflux being a causal factor in chronic rhinosinusitis.

In the paediatric studies, the variability in the results comes from the low numbers used in these studies (mean = 22.5), no controls, the varying diagnostic criteria for CRS in children, GORD diagnostic criteria, selection and data collection bias and other confounding factors such as age, weight, co-morbidity and meals before bedtime. There are no randomised controlled studies and Table 3 shows that on analysis 4 out of the 6 paediatric papers had high risk of bias. As a result of this poor methodology of the papers, good conclusions regarding paediatric cases cannot come from the available evidence at present.

CONCLUSION

In refractory cases of CRS, acid reflux should be kept in mind as the manifestations of CRS and LPR/GORD are so protean as to cause confusion in the diagnosis, and anti-reflux therapy may help for some symptoms. There is no evidence in the literature currently to show a causal link between these very common clinical conditions. Anti reflux treatment should be started if there is clinical or pH probe testing evidence of reflux, but not on nasal symptoms alone.

Some paediatric CRS studies show GORD rates in CRS children to be well above the expected prevalence of GORD in the normal paediatric population, but they are not conclusive. Anti reflux treatment in children should be considered on an individual's symptoms rather than instituting PPI therapy for all CRS patients on this evidence.

Future studies must have robust inclusion criteria to ensure any results can be applied to the correct subset of rhinology patients. Further there must be a correctly randomized controlled trial with sufficient numbers in each group to show that intervention produced a significant difference. The trial should also make note of the inclusion of barrier protection and conservative / lifestyle changes advice in any treatment regimes.

AUTHOR CONTRIBUTIONS

E.P. Flook: researcher, author and B.N. Kumar: supervisor, editor

CONFLICT OF INTEREST

None declared

REFERENCES

1. El-Serag HB, Gilger M, Kuebel M, et al. Extraesophageal associations of gastroesophageal reflux disease in children without neurologic defects. *Gastroenterology* 2001; 121: 1294-1299.
2. Vandenplas Y, Sacre-Smiths L. Continuous 24-hour esophageal pH monitoring in 285 asymptomatic infants 0-15 months old. *J Pediatr Gastroenterol Nutr.* 1987; 6: 220-224.
3. Schindlbeck NE, Heinrich C, Konig A. Optimal thresholds sensitivity and specificity of long-term pH/metry for the detection of gastroesophageal reflux disease. *Gastroenterology* 1987; 93: 85-90.
4. Keles B, Ozturk K, Arbag H, et al. Frequency of pharyngeal reflux in children with adenoid hyperplasia. *Int J Pediatr Otorhinolaryngol* 2005; 69: 1103-7.
5. Critical Appraisal Skills Programme, Oxford, UK <http://www.phru.nhs.uk/Pages/PHD/resources.htm>. [accessed on 20 Aug 2009]
6. Fokkens W, Lund V, Mullol J. EP3OS European position paper on rhinosinusitis and nasal polyps. A summary for the otorhinolaryngologists. *Rhinology* 2007; 45: 97-101.
7. Belafsky PC, Postma GN, Koufman JA. Validity and reliability of the reflux symptom index (RSI). *J Voice* 2002; 16: 274-277.
8. Phipps CD, Wood WE, Gibson WS, et al. Gastroesophageal reflux contributing to chronic sinus disease in children. *Arch Otolaryngol - Head and Neck Surg* 2000; 126: 831-836.
9. Monteiro VRS, Sdepanian VL, Weckx L, et al. Twenty-four-hour esophageal pH monitoring in children and adolescents with chronic and/or recurrent rhinosinusitis. *Braz J Med Biol Res.* 2005; 38: 215-220.
10. Barbero GJ. Gastroesophageal reflux and upper airway disease. *Otolaryngol Clin North Am.* 1996; 29: 27-38.
11. Harris PK, Hussey DJ, Watson DI, et al. Reflux changes in adenoidal hyperplasia: a controlled prospective study to investigate its aetiology. *Clin Otol* 2009; 34: 120-126.
12. Bothwell MR, Parsons DS, Talbot A, et al. Outcome of reflux therapy on pediatric chronic sinusitis. *Otolaryngol - Head Neck Surg* 1999; 121: 255-262.
13. Halstead LA. Role of gastroesophageal reflux in pediatric upper airway disorders. *Otolaryngol - Head Neck Surg* 1999; 120: 208-214.
14. Megale SRMCL, Scanavini ABA, Andrade EC, et al. Gastroesophageal reflux disease: Its importance in ear, nose, and throat practice. *Int J Pediatr Otorhinolaryngol* 2006; 70: 81-88.
15. Ozmen S, Yücel OT, Sinici I, et al. Nasal pepsin assay and pH monitoring in chronic rhinosinusitis. *Laryngoscope* 2008; 118: 890-894.
16. DelGaudio JM. Direct nasopharyngeal reflux of gastric acid is a contributing factor in refractory chronic rhinosinusitis. *Laryngoscope* 2005; 115: 946-957.
17. Ulualp SO, Toohill RJ, Hoffmann R, et al. Possible relationship of gastroesophagopharyngeal acid reflux with pathogenesis of chronic sinusitis. *Am J Rhinol.* 1999; 13: 197-202.
18. Wong IW, Omari TI, Myers JC, et al. Nasopharyngeal pH monitoring in chronic sinusitis patients using a novel four channel probe. *Laryngoscope* 2004; 114: 1582-1585.
19. Jecker P, Orloff LA, Wohlfeil M, et al. Gastroesophageal reflux disease (GERD), extraesophageal reflux (EER) and recurrent chronic rhinosinusitis. *Eur Arch Otorhinolaryngol.* 2006; 263: 664-667.
20. Kibblewhite DJ, Morrison MDA. Double-blind controlled study of the efficacy of cimetidine in the treatment of the cervical symptoms of gastroesophageal reflux. *J Otolaryngol* 1990; 19: 103-109.
21. Kleemann D, Nofz S, Plank I, et al. Gastroesophageal reflux as a cause for delayed healing process after FESS? *HNO* 2005; 53: 333-336.
22. DiBaise JK, Olusola BF, Huerter JV, et al. Role of GERD in chronic resistant sinusitis: A prospective, open label, pilot trial. *Am J Gastroenterol* 2002; 97: 843-850.
23. Pincus RL, Kim HH, Silvers S, et al. A study of the link between gastric reflux and chronic sinusitis in adults. *Ear Nose Throat J.* 2006; 85: 174-178.
24. Dinis P.B., Subtil J. Helicobacter pylori and laryngopharyngeal reflux in chronic rhinosinusitis. *Otolaryngol - Head and Neck Surg* 2006; 134: 67-72.
25. Delehaye E, Dore MP, Bozzo C, et al. Correlation between nasal mucociliary clearance time and gastroesophageal reflux disease: our experience on 50 patients. *Auris Nasus Larynx* 2009; 36: 157-161.
26. Wise SK, Wise JC, DelGaudio JM. Association of nasopharyngeal and laryngopharyngeal reflux with postnasal drip symptomatology in patients with and without rhinosinusitis. *Am J Rhinol.* 2006; 20: 283-289.

EP Flook
17 Willow Way
Manchester, M20 6JT
United Kingdom

Tel: +49-79-3208 1662
E-mail: edflook@yahoo.com